EP Patent

EP2482810A2 — Dosage regimen of an s1p receptor modulator

Assigned to Novartis AG · Expires 2012-08-08 · 14y expired

What this patent protects

S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.

USPTO Abstract

S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.

Drugs covered by this patent

fingolimod-hydrochloride (FINGOLIMOD HYDROCHLORIDE)

Patent Metadata

Patent number: EP2482810A2
Jurisdiction: EP
Classification: —
Expires: 2012-08-08
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.